Nuo Therapeutics (AURX)
OTHER OTC:AURX
Want to see AURX full AI Analyst Report?
AURX Stock Chart & Stats
$2.00
$0.00(0.00%)
At close: 4:00 PM EST
$2.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.94 - $3.23
Previous CloseN/A
Volume8.36K
Average Volume (3M)2.99K
Market Cap
$51.80M
Enterprise Value$48.56M
Total Cash (Recent Filing)$263.83K
Total Debt (Recent Filing)$898.95K
Price to Earnings (P/E)―
Beta0.32
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,408,730
10 Day Avg. Volume655
30 Day Avg. Volume2,988
Financial Highlights & Ratios
PEG Ratio-10.00
Price to Book (P/B)-97.44
Price to Sales (P/S)28.13
P/FCF Ratio-81.78
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue11.75
Enterprise Value/Gross Profit17.96
Enterprise Value/Ebitda-22.31
Forecast
1Y Price Target
$3.00Price Target Upside50.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth (TTM +24.7%) indicates improving product adoption and commercial traction in wound-care markets. Over 2-6 months this supports scale benefits, increases likelihood of continued clinical/provider uptake, and can help absorb fixed costs as commercialization progresses.
High Gross MarginsA ~65% gross margin signals attractive unit economics for Aurix and similar autologous therapies. Durable margin advantage provides operating leverage as revenues grow, allowing reinvestment in R&D and sales while shortening the path to profitability once fixed operating costs are controlled.
Focused Therapeutic NicheA specialized focus on autologous PRP wound therapies targets a persistent clinical need (chronic/hard-to-heal wounds). Structural demand and clinical barriers create a defendable market position, enabling targeted commercialization and potential partnerships with wound-care providers and distributors.
Bears Say
Negative Shareholders' EquityNegative equity materially weakens balance-sheet resilience and limits access to attractive financing. Over months this elevates solvency risk, may trigger restrictive covenants or higher-cost funding, and increases the probability of equity dilution or restructuring if operating losses persist.
Persistent Cash Burn & LossesOngoing negative operating and free cash flow indicate the company cannot self-fund growth and operations. Persisting cash burn forces reliance on external capital, which can delay strategic initiatives, constrain R&D investment, and increase long-term dilution risk if revenue and margin improvements don't accelerate.
Reliance On Structured Debt With Warrant DilutionDependence on secured, insider-linked financing (interest paid in warrants and significant potential share issuance) raises capital structure and governance risks. This durable funding approach increases equity overhang, could dilute shareholders, and signals constrained alternative financing options.
Nuo Therapeutics News
AURX FAQ
What was Nuo Therapeutics’s price range in the past 12 months?
Nuo Therapeutics lowest stock price was $0.94 and its highest was $3.23 in the past 12 months.
What is Nuo Therapeutics’s market cap?
Nuo Therapeutics’s market cap is $51.80M.
When is Nuo Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nuo Therapeutics’s earnings last quarter?
Currently, no data Available
Is Nuo Therapeutics overvalued?
According to Wall Street analysts Nuo Therapeutics’s price is currently Undervalued.
Does Nuo Therapeutics pay dividends?
Nuo Therapeutics does not currently pay dividends.
What is Nuo Therapeutics’s EPS estimate?
Nuo Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuo Therapeutics have?
Nuo Therapeutics has 48,408,730 shares outstanding.
What happened to Nuo Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nuo Therapeutics?
Currently, no hedge funds are holding shares in AURX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuo Therapeutics
Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1998 and is based in Houston, Texas.
AURX Stock 12 Month Forecast
Average Price Target
$3.00
▲(50.00% Upside)
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---